AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial

AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial

<p><strong>Background:</strong> Dolutegravir has superior efficacy and tolerability than lopinavir-ritonavir in second-line antiretroviral therapy after failure of a first-line non-nucleoside reverse transcriptase inhibitors-based regimen, when dolutegravir is accompanied by at lea...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Zhao, Y, Keene, C, Griesel, R, Sayed, K, Gcwabe, Z, Jackson, A, Ngwenya, O, Schutz, C, Goliath, R, Cassidy, T, Goemaere, E, Hill, A, Maartens, G, Meintjes, G
Format:	Journal article
Sprache:	English
Veröffentlicht:	F1000Research 2021

Ähnliche Einträge

AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial [version 1; peer review: 2 approved, 1 approved with reservations]
von: Zimasa Gcwabe, et al.
Veröffentlicht: (2021-02-01)

Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen
von: Keene, CM, et al.
Veröffentlicht: (2021)

Recycling tenofovir in second-line antiretroviral treatment with dolutegravir: outcomes and viral load trajectories to 72 weeks
von: Keene, CM, et al.
Veröffentlicht: (2023)

Virologic outcomes with tenofovir-lamivudine-dolutegravir in adults failing PI-based second-line ART
von: Ying Zhao, et al.
Veröffentlicht: (2024-04-01)

Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
von: Lisi Deng, et al.
Veröffentlicht: (2022-01-01)

Initial supplementary dose of dolutegravir in second-line antiretroviral therapy: a noncomparative, double-blind, randomized placebo-controlled trial
von: Zhao, Y, et al.
Veröffentlicht: (2023)

Assessment of treatment outcomes for HIV Positives transitioned from Tenofovir/Lamivudine/Efavirenz to Tenofovir/Lamivudine/Dolutegravir in a Nigerian Tertiary Hospital
von: Omobola Yetunde Ojo, et al.
Veröffentlicht: (2023-12-01)

HIV-1 pretreatment and acquired antiretroviral drug resistance before tenofovir/ lamivudine /dolutegravir (TLD) roll-out in Mozambique
von: Nália Ismael, et al.
Veröffentlicht: (2024-07-01)

Impact of tenofovir, lamivudine, and dolutegravir on liver function in HIV-positive individuals in Southern Nigeria
von: Odekunle Bola Odegbemi, et al.
Veröffentlicht: (2024-07-01)

The Cost-Effectiveness of Dolutegravir in Combination with Tenofovir and Lamivudine for HIV Therapy: A Systematic Review
von: Aprilianti S, et al.
Veröffentlicht: (2024-01-01)

Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study
von: Hernando Knobel, et al.
Veröffentlicht: (2023-12-01)

Low Prevalence of Pre-Treatment and Acquired Drug Resistance to Dolutegravir among Treatment Naïve Individuals Initiating on Tenofovir, Lamivudine and Dolutegravir in Zimbabwe
von: Vinie Kouamou, et al.
Veröffentlicht: (2023-09-01)

Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens
von: Suntisuklappon Busakorn, et al.
Veröffentlicht: (2010-10-01)

Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial
von: Griesel, R, et al.
Veröffentlicht: (2023)

An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
von: Josep M Llibre, et al.
Veröffentlicht: (2016-01-01)

Retention among transgender women treated with dolutegravir associated with tenofovir/lamivudine or emtricitabine in Argentina: TransViiV study.
von: Claudia E Frola, et al.
Veröffentlicht: (2023-01-01)

Development and validation of stability-indicating HPLC method for simeltaneous determination of Lamivudine, Tenofovir, and Dolutegravir in bulk and their tablet dosage form
von: Nagasarapu Mallikarjuna Rao, et al.
Veröffentlicht: (2015-12-01)

Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy
von: Kairoonisha Mahomed, et al.
Veröffentlicht: (2020-07-01)

Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial [version 1; peer review: 2 approved]
von: Rulan Griesel, et al.
Veröffentlicht: (2021-01-01)

Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies
von: Mounir Ait-Khaled, et al.
Veröffentlicht: (2021-12-01)

Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B
von: Chan Ho Park, et al.
Veröffentlicht: (2016-03-01)

Urine tenofovir and dried blood spot tenofovir diphosphate concentrations and viraemia in people taking efavirenz and dolutegravir based antiretroviral therapy
von: Dorward, J, et al.
Veröffentlicht: (2023)

Efficacy and safety profiles of dolutegravir plus lamivudine vs. bictegravir/emtricitabine/tenofovir alafenamide in therapy-naïve adults with HIV-1
von: Yinghua Wei, et al.
Veröffentlicht: (2023-11-01)

Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
von: Josep M Llibre, et al.
Veröffentlicht: (2016-01-01)

Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies
von: Mark Underwood, et al.
Veröffentlicht: (2024-03-01)

Effectiveness, durability and safety of dolutegravir and lamivudine versus bictegravir, emtricitabine and tenofovir alafenamide in a real-world cohort of HIV-infected adults.
von: Inés Mendoza, et al.
Veröffentlicht: (2023-01-01)

Effectiveness, durability and safety of dolutegravir and lamivudine versus bictegravir, emtricitabine and tenofovir alafenamide in a real-world cohort of HIV-infected adults
von: Inés Mendoza, et al.
Veröffentlicht: (2023-01-01)

The impact of adherence counseling incorporating a point of care urine tenofovir assay on virologic suppression among individuals failing tenofovir-lamivudine-dolutegravir: A pre-post intervention study
von: Leonard Bikinesi, et al.
Veröffentlicht: (2025-02-01)

Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
von: Zamora FJ, et al.
Veröffentlicht: (2019-10-01)

Dolutegravir for second-line treatment: Programmatic implications of new evidence
von: Ying Zhao, et al.
Veröffentlicht: (2022-09-01)

Lamivudine-resistant HIVM184V is durably suppressed with dolutegravir plus lamivudine dual therapy in humanised mice
von: Sandra Medina-Moreno, et al.
Veröffentlicht: (2020-03-01)

Real-World Effectiveness, Tolerability, and Safety of Dolutegravir/Lamivudine in Korea
von: Ki Hyun Lee, et al.
Veröffentlicht: (2022-11-01)

Brief communication: efficacy and safety of the dolutegravir/lamivudine dual therapy in antiretroviral treatment-experienced Chinese people living with HIV
von: Zhenyan Wang, et al.
Veröffentlicht: (2024-11-01)

Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir Plus Lamivudine for Switch Therapy in Patients with HIV-1 Infection: A Real-World Cohort Study
von: Lin Gan, et al.
Veröffentlicht: (2023-10-01)

Laboratory Based Surveillance of HIV-1 Acquired Drug Resistance in Cameroon: Implications for Use of Tenofovir-Lamivudine-Dolutegravir (TLD) as Second- or Third-Line Regimens
von: Joseph Fokam, et al.
Veröffentlicht: (2023-08-01)

Qualitative study exploring the experiences and perceptions of dolutegravir/lamivudine dual antiretroviral therapy (the PEDAL study) in people living with HIV: protocol
von: Amanda Clarke, et al.
Veröffentlicht: (2022-05-01)

Evolution of Self-reported Neuropsychiatric Symptoms After Switching from Dolutegravir/Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Results from the Randomized DOBINeuro Trial
von: Barbara Rossetti, et al.
Veröffentlicht: (2024-11-01)

Systematic De-escalation of Successful Triple Antiretroviral Therapy to Dual Therapy with Dolutegravir plus Emtricitabine or Lamivudine in Swiss HIV-positive Persons
von: Natascha D. Diaco, et al.
Veröffentlicht: (2018-12-01)

Interactions of Tenofovir, Lamivudine, Abacavir and Didanosine in Primary Human Cells
von: Saye H. Khoo, et al.
Veröffentlicht: (2011-06-01)

Selenium abrogates tenofovir/lamivudine/efavirenz-induced hepatotoxicity in rats
von: Elias Adikwu, et al.
Veröffentlicht: (2021-01-01)